WVE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

WV

Mkt Cap

$615.4M

Volume

2.57M

Next Earnings

November 9th

Loading chart

WV

WVEWave Life Sciences Ltd. Ordinary Shares

WVE

Pay with—

Available Balance0.00

WV

Mkt Cap

$616.8M

Volume

2.57M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsightOver 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.GlobeNewswire Inc. · Oct 15, 2026

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsightThe oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.GlobeNewswire Inc. · May 14, 2026

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA PathWave Life Sciences regained full rights to WVE-006 from GSK for treating alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder. Wave plans to accelerate the registrational strategy and pursue an accelerated FDA approval pathway, with regulatory feedback expected mid-2026. Clinical trial data from the RestorAATion-2 trial is on track for Q1 2026. WVE stock rose 4.48% on the announcement.Benzinga · Feb 2, 2026

Golden Cross Alert: 3 Stocks With Major Upside PotentialThe article highlights three stocks showing potential for upside momentum in 2026 based on golden cross technical signals and fundamental analysis: Sun Communities, Darling Ingredients, and Wave Life Sciences.Investing.com · Dec 11, 2025

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsWave Life Sciences announced a public offering of 15,789,475 ordinary shares and pre-funded warrants, expecting to raise approximately $350 million to support its RNA medicines platform and clinical programs.GlobeNewswire Inc. · Dec 10, 2025

Why Wave Life Sciences Stock Crushed it Again TodayWave Life Sciences experienced a significant stock surge following positive Phase 1 clinical study results for its obesity drug candidate WVE-007, with analysts upgrading price targets and recommendations.The Motley Fool · Dec 10, 2025

Why Wave Life Sciences Stock Vaulted 146% Higher on MondayWave Life Sciences saw a massive stock surge after reporting promising phase 1 clinical trial results for its investigational weight loss drug WVE-007, which demonstrated significant body fat reduction and potential competitive advantages over existing GLP-1 drugs.The Motley Fool · Dec 8, 2025

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025Wave Life Sciences presented preclinical data for WVE-007, a novel RNA medicine targeting obesity by silencing INHBE mRNA. Preclinical studies showed potential for fat loss while preserving muscle mass, with promising initial clinical trial results demonstrating significant Activin E reduction.GlobeNewswire Inc. · Nov 5, 2025

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research DayWave Life Sciences reported significant Activin E reductions of up to 85% in its INLIGHT clinical trial for obesity treatment, with WVE-007 showing promising results in fat loss potential and safety profile across multiple dose cohorts.GlobeNewswire Inc. · Oct 30, 2025

Wave (WVE) Q2 Revenue Drops 56%Wave Life Sciences reported a challenging Q2 2025, with revenue declining 55.8% to $8.7 million and a net loss of $50.5 million. Despite financial setbacks, the company continues to advance its RNA-based medicine pipeline across multiple therapeutic areas.The Motley Fool · Jul 31, 2025

to start trading

WV

WVEWave Life Sciences Ltd. Ordinary Shares

WVE

Pay with—

Available Balance0.00

Your PositionYou don't own any WVE yet.

Related Tickers

Earnings